ERBB2 and breast cancer: Therefore, the conventional targeted HER2 therapy by monoclonal antibodies appears not to be an appropriate choice for HER2-low BC, since its activity basically consists of blocking the aberrant HER2 signaling (via dimerization inhibition) and the antibody-dependent cellular cytotoxicity [61].